Giannis Mountzios: Biomarker-selected or biomarker-agnostic ADCs for oncogene-addicted NSCLC

Giannis Mountzios: Biomarker-selected or biomarker-agnostic ADCs for oncogene-addicted NSCLC

Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared his recent article on X:

“Biomarker-selected or biomarker-agnostic ADCs for oncogene-addicted NSCLC

Just out in ESMO Cancer Treatment Reviews a comprehensive overview on current landscape, challenges and perspectives.

Grateful to work with a global amazing team, including Stephanie Saw, Lizza Hendriks, Jessica Menis, Tina Cascone, Oscar Arrieta, Jarushka Naidoo, Alfredo Addeo, Solange Peters and senior author Jordi Remon.”

Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target

Authors: Giannis Mountzios, et al.

Giannis Mountzios: Biomarker-selected or biomarker-agnostic ADCs for oncogene-addicted NSCLC

 

Alfredo Addeo cancer ESMO Cancer Treatment Reviews fight against cancer genomic alterations Giannis Mountzios Global awareness Global fight against cancer Henry Dunant Hospital Center Jarushka Naidoo Jessica Menis Jordi Remon Lizza Hendriks NSCLC OncoDaily Oncology Oscar Arrieta Solange Peters Stephanie Saw Tina Cascone